Added to YB: 2026-01-07
Pitch date: 2025-12-03
NVO [bullish]
Novo Nordisk A/S
-1.25%
current return
Author Info
Alpha Talon Investment Research is a Hong Kong–based private family office deploying only proprietary capital across biotech, value turnarounds, and catalyst-driven shorts, focused on intrinsic value, regulatory odds, and mispriced fundamentals. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.3T
Pitch Price
DKK 304.80
Price Target
180.00 (-41%)
Dividend
3.89%
EV/EBITDA
9.31
P/E
13.07
EV/Sales
4.67
Sector
Pharmaceuticals
Category
growth
Novo Nordisk: From Insulin Giant to Global Metabolic Infrastructure
NVO: facing unprecedented competition - Lilly advancing faster w/ superior next-gen efficacy; Pfizer's Metsera acquisition intensifies landscape. Bull case: oral GLP-1 unlock, $330B+ revenue, 84%+ gross margins, massive CapEx expansion creating multi-decade platform. Bear case: competitive displacement, manufacturing bottlenecks. DCF targets $165-180 base case. Execution-critical investment w/ asymmetric outcomes.
Read full article (22 min)